MERS-CoV is the coronavirus most people forgot about. Since the first human case was identified in Jeddah in June 2012, WHO has tallied roughly 2,600 confirmed infections across 27 countries, with case fatality near 35 percent and more than 80 percent of cases in Saudi Arabia. That fatality is the highest of any coronavirus producing sustained human outbreaks.
For travelers, the picture is unusual. MERS-CoV is not a mass-gathering spreader like influenza, and not a community spreader like SARS-CoV-2. It is a zoonosis with a short fuse for nosocomial chains: camel contact starts most cases, hospitals amplify them, and the rest of the population sees almost nothing until a returning traveler walks into an ER. This post fits inside outbreak-aware travel and pairs with the Hajj and Umrah disease risk post for pilgrims planning Saudi travel.
Key Takeaways
- WHO has confirmed about 2,600 MERS-CoV cases since 2012, with more than 80 percent in Saudi Arabia.
- Case fatality runs near 35 percent. Older adults and people with diabetes, chronic kidney disease, or immunosuppression carry the worst outcomes.
- Dromedary camels are the intermediate host. Spillover happens through close contact, raw camel milk, undercooked meat, or aerosols around barns and racetracks.
- Sustained community transmission has not occurred. Almost all secondary cases trace to healthcare exposures or household care of severely ill patients.
- No licensed human vaccine exists. CEPI has funded candidates including the Oxford ChAdOx1 MERS vaccine that informed the COVID-19 platform.
- Travelers returning from the Arabian Peninsula with acute respiratory illness within 14 days should mention the travel history so RT-PCR testing is ordered.
What is MERS-CoV?
MERS-CoV (Middle East Respiratory Syndrome coronavirus) is a betacoronavirus in the same genus as SARS-CoV-1 and SARS-CoV-2. It causes severe lower respiratory illness with fever, cough, and shortness of breath that progresses to pneumonia and ARDS in roughly half of confirmed cases. The virus was first isolated from a Saudi patient in 2012.
The natural reservoir is bats; serology suggests bat-to-camel spillover happened decades or centuries ago. Dromedary camels (Camelus dromedarius) are now the established intermediate host, with calves shedding most actively. Serosurveys across Saudi Arabia, the UAE, Oman, and parts of East Africa show 70 to 95 percent of adult dromedaries have antibodies.
Where has MERS-CoV been reported?
Twenty-seven countries have reported confirmed cases since 2012, but the geography is concentrated. Saudi Arabia accounts for the vast majority. The UAE, Jordan, Qatar, Oman, Iran, Kuwait, Yemen, and Bahrain have reported cases tied to local camel exposure. Outside the Arabian Peninsula, almost every confirmed case has been imported in a returning traveler, sometimes with onward nosocomial transmission.
| Year | Country | Cases | Notes |
|---|---|---|---|
| 2012 | Saudi Arabia | First detection | Jeddah index case, June 2012 |
| 2013 to 2014 | UAE, Jordan, Qatar | Sporadic clusters | Camel barn exposures |
| 2014 | United States | 2 imported | Healthcare workers from Saudi |
| 2015 | South Korea | 186 | One imported case, 36 deaths |
| 2018 | UK | 1 imported | Returning Saudi traveler |
| 2019 to 2025 | Saudi Arabia, UAE | ~100 to 200/yr | Steady camel-linked spillover |
The 2015 South Korea outbreak is the largest cluster outside the Arabian Peninsula. A 68-year-old businessman returned from a Middle East trip, was diagnosed late, and seeded transmission across four hospitals through ED crowding and shared rooms. Korean authorities documented 186 secondary cases and 36 deaths within two months. No community spread occurred once isolation procedures were enforced.
How does camel exposure cause spillover?
Spillover happens through three routes: direct contact with infected camels (saliva, nasal secretions, urine), raw camel milk, and aerosols around barns, markets, and racetracks. Transmission is most efficient from young camels actively shedding virus and from camels recently brought together for racing, breeding, or sale.
Documented risks include camel farm and slaughterhouse work, tourist camel markets, raw camel milk, and undercooked camel meat. Pasteurized milk and well-cooked meat have not been linked to cases. WHO advice for visitors to the Arabian Peninsula is to skip petting farms and racetracks, avoid raw camel products, and wash hands after any unavoidable contact.
What are the symptoms and case fatality rate?
Symptoms start 2 to 14 days after exposure and look like severe pneumonia: high fever, cough, shortness of breath, and rapidly progressive hypoxia. Some patients develop GI symptoms (diarrhea, nausea, vomiting) before respiratory signs appear. About half of hospitalizations progress to ARDS, often requiring mechanical ventilation and renal replacement therapy.
Case fatality sits at roughly 35 percent. That figure is almost certainly inflated by under-detection of mild infections; serosurveys in camel-contact populations have found antibody-positive individuals with no recall of severe illness. Even a real fatality of 10 to 15 percent would be catastrophic in a pathogen with efficient transmission. Risk factors for death include age over 50, diabetes, chronic kidney disease, chronic lung disease, immunosuppression, and pregnancy.
Why does MERS-CoV cause hospital outbreaks?
The pattern repeats: a patient with vague respiratory symptoms is admitted to a busy emergency department, MERS-CoV is not on the differential, isolation is delayed, and aerosol-generating procedures (intubation, nebulizers, bronchoscopy) seed staff and other patients. The 2015 Korea outbreak ran this script, as did Saudi clusters in 2013, 2014, and 2019. The virus is contact-and-droplet in most settings but produces aerosols during procedures, when in-hospital amplification happens.
Three factors push MERS-CoV above its community R0 inside hospitals: crowded ERs with shared bay space, family caregivers who stay overnight (a cultural norm in Korea and the Gulf), and delayed diagnosis meaning days of unprotected contact before isolation begins. Once airborne and contact precautions go in, outbreaks die out fast.
What is the travel risk for Hajj pilgrims and other visitors?
Risk for ordinary tourists and Hajj or Umrah pilgrims is low but not zero. Pilgrim-to-pilgrim transmission at Hajj has been documented but is rare; the larger risk has always been camel exposure during pre-Hajj or post-Hajj travel rather than the rituals themselves. Saudi authorities advise pilgrims to avoid camel barns, racetracks, and farms, and to skip raw camel milk and meat.
Practical steps for any visitor to the Arabian Peninsula:
- Skip camel-petting tourist sites in Riyadh, Dubai, and Doha
- Do not drink raw camel milk, even when offered as hospitality
- Eat camel meat only when thoroughly cooked
- Wash hands after any unavoidable camel contact
- If you develop fever, cough, or shortness of breath within 14 days of return, mention the travel history at first presentation
For people with diabetes, chronic kidney or lung disease, immunosuppression, or those over 65, avoiding camels entirely is the right call. These groups carry most of the documented mortality.
What treatment, vaccine, and surveillance exist?
No specific antiviral has proven mortality benefit. Care is supportive: oxygen, mechanical ventilation, prone positioning, ECMO when available, and renal replacement therapy. Remdesivir has activity in animal models and has been used compassionately, but no controlled human trial has shown survival benefit.
CEPI has funded several human vaccine candidates since 2017. The Oxford ChAdOx1 MERS vaccine, built on the viral-vector platform that later became the AstraZeneca COVID-19 vaccine, reached Phase Ib in Saudi Arabia in 2019 to 2020. Inovio's DNA candidate and mRNA approaches have moved through early trials. A camel vaccine using modified vaccinia virus Ankara has shown protection in trials and is under consideration for Saudi herd deployment. None is yet licensed for humans.
Surveillance runs through the Saudi Ministry of Health, WHO's Eastern Mediterranean office, and GOARN. WHO requires immediate notification under IHR for every case. See zoonotic diseases explained for the spillover framework and novel pathogens explained for WHO's priority pathogen list.
The three coronaviruses that have produced human outbreaks share a betacoronavirus ancestry but differ on the variables that shape outbreaks:
| Feature | MERS-CoV | SARS-CoV (2003) | SARS-CoV-2 |
|---|---|---|---|
| First detected | 2012, Saudi Arabia | 2002, China | 2019, China |
| Total confirmed cases | ~2,600 | ~8,100 | >700 million |
| Case fatality | ~35% | ~10% | ~0.5 to 2% |
| Reservoir | Bats via camels | Bats via civets | Bats, intermediate uncertain |
| Sustained community spread | No | No | Yes |
| Vaccine licensed | No | No | Yes |
MERS-CoV is the cautionary story. High lethality, established animal reservoir, ongoing spillover, and proven nosocomial amplification, but no efficient human-to-human transmission yet. The bet public health is making is that the virus does not adapt the way SARS-CoV-2 did. Camel vaccination, hospital infection control, and a shelf-ready human vaccine are the three insurance policies.
FAQ
Can you get MERS-CoV from pasteurized camel milk?
No documented case has been linked to pasteurized camel milk. Pasteurization at standard dairy temperatures inactivates MERS-CoV reliably. The risk is from raw, unpasteurized milk, traditional in Bedouin and Gulf households and sold by some health-food retailers. The same rule applies to camel cheese and yogurt made with raw milk.
How long does MERS-CoV stay infectious on surfaces?
Laboratory studies show MERS-CoV remains viable on stainless steel and plastic for up to 48 hours at room temperature, longer in cool low-humidity conditions. It is sensitive to alcohol, bleach, hydrogen peroxide, and sunlight. Hospital surface contamination has been documented, which is why terminal-clean protocols are part of every nosocomial response.
Why is MERS-CoV not a pandemic when SARS-CoV-2 became one?
R0 is the difference. MERS-CoV human-to-human transmission sits well below 1.0 in community settings, meaning each case typically infects fewer than one further person. SARS-CoV-2 entered the human population with R0 around 2 to 3. A change in spike-protein receptor binding could shift the picture, which is what surveillance is watching for.
Should I get tested for MERS-CoV after a Saudi trip?
Only if you develop respiratory symptoms within 14 days of return. Routine post-travel testing in asymptomatic travelers is not recommended. If you develop fever, cough, or shortness of breath in that window, tell the clinician you returned from the Arabian Peninsula and ask for MERS-CoV RT-PCR.
Is there any vaccine I can get before traveling?
No licensed human MERS-CoV vaccine exists as of 2026. The Oxford ChAdOx1 MERS vaccine completed Phase Ib trials but is not commercially available. Pre-travel planning should focus on routine immunizations, MenACWY for Hajj or Umrah pilgrims, influenza, and COVID-19 boosters.